Navigation Links
Medarex Announces 2007 Fourth Quarter and Year End Financial Results
Date:2/26/2008

), and (iii) approximately $2.7 million of increased costs associated with the development of ipilimumab (MDX-010). General and administrative expenses decreased by $5.0 million for the year ended December 31, 2007, from $51.9 million in 2006 to $46.9 million in 2007. The 2007 decrease is primarily attributable to lower legal and other professional fees.

Medarex ended 2007 with approximately $348.8 million in cash, cash equivalents and marketable securities. Approximately $4.9 million of this balance relates to Celldex. In addition, the fair market value of Medarex's equity interest in Genmab was approximately $291.2 million as of December 31, 2007.

For the three-month period ended December 31, 2007, Medarex reported a net loss of $44.8 million, or ($0.35) per share. This compares to a net loss of $57.7 million, or ($0.46) per share for the three-month period ended December 31, 2006. Included in the consolidated net loss for the three-month period ended December 31, 2007 is a net loss of $3.7 million, or ($0.03) per share representing Medarex's share of the net loss of Celldex for the period and a non-cash charge of $4.8 million, or ($0.04) per share for stock based compensation expense recorded in accordance with FAS 123(R). Excluding the impact of these items, Medarex's net loss on a non-GAAP basis for the three- month period ended December 31, 2007 was $36.3 million, or ($0.29) per share.

Non-GAAP Financial Measurements

This press release and the accompanying tables include non-GAAP financial measures. Please see the section of the accompanying tables titled "Reconciliation of GAAP Net Loss to Non-GAAP Net Loss" for a description of these non-GAAP financial measures, including reasons for Medarex management's decision to use each measure, and reconciliations of these non-GAAP financial measures to the most directly comparable financial measures prepared in accordance with Generally Accepted Accounting Principles.

Medarex's produ
'/>"/>

SOURCE Medarex, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12

Related medicine news :

1. Medarex to Present at the Merrill Lynch Global Pharmaceutical, Biotechnology & Medical Device Conference
2. Medarex to Receive Milestone Payment for Submission of Regulatory Applications Requesting Approval of Ustekinumab (CNTO 1275) for Treatment of Psoriasis
3. PharmAthene and Medarex Announce Additional $0.8 Million U.S. Government Appropriation for Continued Development of Anthrax Therapeutic Valortim(TM)
4. Medarex to Present at the JPMorgan Small/Mid Cap Conference
5. Ono and Medarex Announce Allowance of Investigational New Drug Application for Fully Human Anti-PD1 Antibody
6. Grupo Casa Saba Announces Fourth Quarter 2007 Results
7. Lixte Biotechnology Holdings, Inc. Announces Further Developments Regarding the Anti-Cancer Activity of Its Patent-Pending Proprietary Compounds
8. Reproductive Medicine Associates of Texas Announces Open House in San Antonio
9. WallSt.net (www.WallSt.net) Announces Upcoming Interview With Chairman and CEO of flexSCAN, Inc.
10. Hospira Announces New Contract With HealthTrust Purchasing Group for Infusion Devices, Solutions and Equipment
11. Thomson Healthcare Announces Enhancements to Order Sets Solution
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/28/2014)... Camp Soaring Eagle today announced it ... Cornville, AZ. The nonprofit organization, founded in July ... to attend medically supervised camps at no cost ... a variety of programs to Arizona families and ... illnesses including: Illness Specific Camping Weekends, Illness Specific ...
(Date:7/28/2014)... July 28, 2014 An estimated 68,000 ... from metastatic breast and prostate cancers – an aggressive ... has spread to other parts of the body, such ... at Drexel University College of Medicine have ... that inhibits metastatic progression by blocking tumor cells from ...
(Date:7/28/2014)... surgical procedure to treat severe chronic migraine headaches led ... the time in patients treated at Massachusetts General Hospital ... and Reconstructive Surgery report that more than half of ... of whom had headaches associated with compression of craniofacial ... The team,s paper has received advance online publication ...
(Date:7/28/2014)... 28, 2014 Glutamine is the most ... considered to be conditionally essential during times when the ... advanced recovery & Immune System Support. , Having a ... body produces, supplementing with additional glutamine may be advantageous. ... in the body, digestion and immune system function. Stress ...
(Date:7/28/2014)... --,The more chronic medical conditions people have at retirement ... new study claims. Since nearly four in ... Johns Hopkins Bloomberg School of Public Health in Baltimore ... life expectancy are slowing in the United States. ... disease and heart failure is now the norm and ...
Breaking Medicine News(10 mins):Health News:Camp Soaring Eagle Announces New Camp Site 2Health News:Camp Soaring Eagle Announces New Camp Site 3Health News:Drexel Scientists Develop Compound to Stop Spread of Metastatic Cancer Cells 2Health News:Drexel Scientists Develop Compound to Stop Spread of Metastatic Cancer Cells 3Health News:Non-endoscopic migraine surgery provides significant symptom relief 2Health News:Betancourt Nutrition Introduces Glutamine Plus with Sustamine® L-Alanyl-L-Glutamine 2Health News:Betancourt Nutrition Introduces Glutamine Plus with Sustamine® L-Alanyl-L-Glutamine 3Health News:Chronic Medical Conditions Can Shorten Seniors' Lives: Study 2
... , ... on COPD and Immuno-Therapeutic Cancer Treatment , ... San Diego, CA (PRWEB) November 10, 2009 -- Entest BioMedical, ... immuno-therapeutic treatment of cancer and Chronic Obstructive Pulmonary Disease (COPD) and their potential to ...
... LOS ANGELES, Nov. 10 Research conducted by the Center ... on the effects of a popular form of hyperbaric oxygen ... The "Randomized Trial of Hyperbaric Oxygen Therapy for Children with ... at 1.3 atmospheres of pressure, does not have a significant ...
... , ... At a time when health is a major concern for ... Pha-max, an internationally recognized company, has opened its doors in the United ... about their health and what better time to have options than now. ...
... , ... Advanced Vibration Exercise), a North American company, is expanding its cutting edge vibration exercise ... revolutionary vibration platforms, the Pro Elite, Air Reflex and Contour Plus, are now available ... ...
... ... child and family therapy pioneer B. Bryan Post is creating content ... emotional development for Miracle Industries, LLC., makers of the world-famous swadder ... will offer a valuable online resource for parents as well as ...
... Patrick, and Lieutenant Governor Murray , BOSTON, Nov. 9 ... P. McGovern (D-Worcester) called for all of the state,s hospitals ... their care. , "With 554,000 people in Massachusetts now ... Memorial Health Care in Worcester, "we have a problem that ...
Cached Medicine News:Health News:Entest BioMedical, Inc. Discusses How Therapies in Development May Yield Lucrative Revenue Streams for the Company 2Health News:Entest BioMedical, Inc. Discusses How Therapies in Development May Yield Lucrative Revenue Streams for the Company 3Health News:Center for Autism and Related Disorders Study Finds Hyperbaric Oxygen Therapy Ineffective Treatment for Children with Autism 2Health News:Major Biotechnology Franchise Company Expands Rapidly Throughout the USA Amidst Mounting Health Concerns 2Health News:WAVE's Revolutionary Whole-Body Advanced Vibration Exercise Is Now Available in South America 2Health News:Attachment & Emotional Development Expert Teams Up with Miracle Industries, LLC. to Launch Valuable Parenting Resource 2Health News:Attachment & Emotional Development Expert Teams Up with Miracle Industries, LLC. to Launch Valuable Parenting Resource 3Health News:Attachment & Emotional Development Expert Teams Up with Miracle Industries, LLC. to Launch Valuable Parenting Resource 4Health News:McGovern and Project Bread Launch Hospital Hunger Initiative 2Health News:McGovern and Project Bread Launch Hospital Hunger Initiative 3
(Date:7/28/2014)... New Zealand , July 28, 2014 /PRNewswire/ ... in Sweden has validated ... multiple vendor platforms and has associated volumetrically assessed ... in Cancer Epidemiology, Biomarkers & Prevention ... mammographic density: a tool for widespread breast cancer ...
(Date:7/28/2014)... July 28, 2014  ALPHAEON Corporation ... healthcare and subsidiary of Strathspey Crown ... Recommended Nutriceuticals (PRN) ® , a leading ... products for dry eye and macular ... transaction worth up to $55M. ...
(Date:7/28/2014)... July 28, 2014 ... 2,5 Millionen £ investiert hat, um die ... Gesundheits-, Pharma- und Logistikbranche zu erfüllen. Albion ...      (Photo: http://photos.prnewswire.com/prnh/20140728/697982 ) ... OmPrompt sein beschleunigtes Wachstum mit Investitionen in ...
Breaking Medicine Technology:Karolinska Study Published in Cancer Epidemiology, Biomarkers & Prevention Validates Strong Agreement for VolparaDensity across Mammography Systems from Multiple Manufacturers 2Karolinska Study Published in Cancer Epidemiology, Biomarkers & Prevention Validates Strong Agreement for VolparaDensity across Mammography Systems from Multiple Manufacturers 3Karolinska Study Published in Cancer Epidemiology, Biomarkers & Prevention Validates Strong Agreement for VolparaDensity across Mammography Systems from Multiple Manufacturers 4ALPHAEON Acquires PRN, A Leading Specialty Nutriceutical Company 2ALPHAEON Acquires PRN, A Leading Specialty Nutriceutical Company 3OmPrompt erhält Finanzierung für Marktexpansion von Kundenautomatisierungsmanagement 2
... PharmaMar SA (Grupo Zeltia, ZEL.MC) has announced ... for patients with solid tumors. PM060184 is a marine-derived, synthetically-produced ... in vivo antitumor activity and a favorable safety ... in clinical development. The trials will be performed ...
... Feb. 7, 2011 Pharmasset, Inc. (Nasdaq: ... discovering, developing, and commercializing novel drugs to treat viral ... the quarter ended December 31, 2010. ... ended December 31, 2010 compared to $0.3 million for ...
Cached Medicine Technology:PharmaMar Commences Clinical Trial in U.S. with New Antitumor Product, PM060184 2Pharmasset Reports Fiscal First Quarter 2011 Financial Results 2Pharmasset Reports Fiscal First Quarter 2011 Financial Results 3Pharmasset Reports Fiscal First Quarter 2011 Financial Results 4Pharmasset Reports Fiscal First Quarter 2011 Financial Results 5Pharmasset Reports Fiscal First Quarter 2011 Financial Results 6
Flexible rake retractor, 3 blunt prongs....
Bayonet dressing forceps serrated jaws...
Medpor Encophthalmos Wedge mimics the contour of the orbital floor and provides volume to restore the orbit to its normal shape and size....
Medpor 2/3 Orbit implants are designed to replace non load bearing bony structures in the orbital area....
Medicine Products: